News Archive

Cantargia shows in-vivo proof of concept in malignant melanoma »
12-02-09

More attention on Cantargia in the internationally recognized magazine "BioCentury" »
12-01-31

ProNoxis has secured SEK 4.0 million in a new round of financing »
12-01-25

New rights issue in LU Bio February 2012 »
12-01-18

LUIS - LU Bio collaboration generates two new companies »
11-08-30

New investment in ProNoxis »
11-06-17

Attention on XImmune in BioCentury »
11-04-13

Cantargia builds power »
11-02-21

Continued progress in XImmune »
11-02-07

LU Bio acknowledged in high profile publication SciBX »
11-01-22

LU Bio sales of holdings »
10-12-08

Report on LU Bio portfolio company ProNoxis published in BioCentury »
10-10-07

LU Bio has decided to close the portfolio company Auril »
10-09-30

Article on Cantargia published in SciBX regarding “Homing in on CML stem cells“ »
10-09-17

LU Bio and Bio-Medisinsk Innovasjon AS in Oslo starts new co-operation »
10-09-13

LU Bio portfolio company Cantargia in the newsroom »
10-08-31

LU Bio dispose Oncorel holdings »
10-04-14

LU Bio portfolio company XImmune in the newsroom »
10-03-25

Dermagen reports successful phase I/IIa clinical trial »
09-12-02

LU Bioscience increases position in ProNoxis »
09-11-12

Successful findings from our portfolio company Auril noticed »
09-09-07

New investment dealing with temperature reduction in patients »
09-06-23

LU Bio announces a continued investment in Cytoguide ApS »
09-06-02

New portfolio company ProNoxis established »
09-06-01

Open seminar at Biomedical Center, Lund University, on March 25 »
09-03-15

LU Bio acknowledged in high profile publication SciBX

Share

| Print |

Tell a colleague

Tell a colleague about this

Your name

Recipient E-mail

Share this page

Google Bookmarks

Science-Business eXchange, SciBX, a weekly publication that unites the scientific acumen of Nature Publishing Group with the business intelligence of BioCentury Publications has published a feature about LU Bio. SciBX´s aim is to provide analysis of the scientific content and commercial potential of the most important translational research papers with the potential to transform human therapeutics and diagnostics.

Click here to read the SciBX article about LU Bio

+46 (0)46 286 48 20
info@lubio.se

Ideon, Alfa 5
SE 223 70 Lund, Sweden

Lund University Bioscience AB

Contact us